Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$8.35

0.2 (2.45%)

07:19
01/08/18
01/08
07:19
01/08/18
07:19

Iovance to 'vigorously defend' against shareholder derivative complaint

Iovance Biotherapeutics disclosed that on December 15, 2017, a purported shareholder derivative complaint, Kevin Fong v. Manish Singh, was filed against the company, as nominal defendant, and certain of the company's current and former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware. The complaint alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934 and Rule 14a-9 promulgated thereunder arising from the Securities and Exchange Commission's investigation in the In the Matter of Certain Stock Promotions matter and the Company's April 10, 2017 settlement thereof, and seeks unspecified damages on behalf of the Company and injunctive relief, Iovance said. It added, "The Company intends to vigorously defend against the foregoing complaint. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of the matter."

IOVA Iovance Biotherapeutics
$8.35

0.2 (2.45%)

08/03/17
OPCO
08/03/17
INITIATION
Target $13
OPCO
Outperform
Iovance Biotherapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Iovance Biotherapeutics with an Outperform and a $13 price target saying its tumor infiltrating lymphocytes therapy has been clinically validated by several academic institutions and expects to see a stream of clinical readouts from three ongoing company-sponsored trials in the next 12-18 month. Breidenbach expects lovance's path to commercialization in solid tumors to be simplified due to to the trailblazing of personalized CAR-T therapies for blood cancers.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.

TODAY'S FREE FLY STORIES

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

16:31
01/19/18
01/19
16:31
01/19/18
16:31
Hot Stocks
Andeavor Logistics raises quarterly cash distribution to $1.00 per unit »

The fourth quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

16:30
01/19/18
01/19
16:30
01/19/18
16:30
Options
Preliminary option volume of 22.8M today »

Preliminary option volume…

TRNC

tronc

$19.53

0.3 (1.56%)

16:26
01/19/18
01/19
16:26
01/19/18
16:26
Periodicals
LA Times' CEO Ross Levinsohn to take leave of absence amid probe, DJ says »

Dow Jones added that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RKDA

Arcadia Biosciences

$0.27

0.0285 (11.88%)

16:25
01/19/18
01/19
16:25
01/19/18
16:25
Conference/Events
Arcadia Biosciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

16:23
01/19/18
01/19
16:23
01/19/18
16:23
Hot Stocks
Facebook provides update on trusted sources initiative »

Starting next week,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

MS

Morgan Stanley

$57.46

1.62 (2.90%)

, APO

Apollo Global

$34.74

-0.33 (-0.94%)

16:21
01/19/18
01/19
16:21
01/19/18
16:21
Hot Stocks
Morgan Stanley reports 5% passive stake in Apollo Global »

In a regulatory filing,…

MS

Morgan Stanley

$57.46

1.62 (2.90%)

APO

Apollo Global

$34.74

-0.33 (-0.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 01

    Feb

HBNC

Horizon Bancorp

$28.49

0.37 (1.32%)

16:19
01/19/18
01/19
16:19
01/19/18
16:19
Syndicate
Breaking Syndicate news story on Horizon Bancorp »

Horizon Bancorp files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

16:18
01/19/18
01/19
16:18
01/19/18
16:18
Hot Stocks
Breaking Hot Stocks news story on Sanmina »

Sanmina down 15% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

16:17
01/19/18
01/19
16:17
01/19/18
16:17
Hot Stocks
Sanmina adopts consolidated restructuring plan »

On January 12, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$162.37

-6.75 (-3.99%)

, AXP

American Express

$98.03

-1.83 (-1.83%)

16:17
01/19/18
01/19
16:17
01/19/18
16:17
General news
On The Fly: Top stock stories for Friday »

Stocks were mixed for…

IBM

IBM

$162.37

-6.75 (-3.99%)

AXP

American Express

$98.03

-1.83 (-1.83%)

GE

General Electric

$16.26

-0.51 (-3.04%)

FB

Facebook

$181.29

1.49 (0.83%)

NCNA

NuCana

$20.51

6.02 (41.55%)

ACOR

Acorda Therapeutics

$27.20

2.2 (8.80%)

BIIB

Biogen

$342.41

-2.03 (-0.59%)

IPHI

Inphi

$32.07

-3.33 (-9.41%)

MKC

McCormick

$99.19

-3.72 (-3.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

  • 08

    Mar

$NSD

NASDAQ Market Internals

16:17
01/19/18
01/19
16:17
01/19/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
01/19/18
01/19
16:16
01/19/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENDP

Endo

$7.11

-0.24 (-3.27%)

, CVS

CVS Health

$79.85

0.5 (0.63%)

16:15
01/19/18
01/19
16:15
01/19/18
16:15
Periodicals
Delaware files lawsuit against opioid manufacturers, distributors, Reuters says »

Delaware has become the…

ENDP

Endo

$7.11

-0.24 (-3.27%)

CVS

CVS Health

$79.85

0.5 (0.63%)

WBA

Walgreens Boots Alliance

$76.47

0.47 (0.62%)

MCK

McKesson

$170.33

-1.45 (-0.84%)

CAH

Cardinal Health

$71.90

0.19 (0.26%)

ABC

AmerisourceBergen

$100.01

-0.85 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 06

    Feb

  • 08

    Feb

ITI

Iteris

$7.49

0.03 (0.40%)

16:12
01/19/18
01/19
16:12
01/19/18
16:12
Hot Stocks
Neil Subin sells $748K in Iteris shares »

Neil Subin, a beneficial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SANM

Sanmina

$35.45

0.5 (1.43%)

16:11
01/19/18
01/19
16:11
01/19/18
16:11
Earnings
Sanmina sees Q2 adjusted EPS 40c-50c, consensus 70c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

16:09
01/19/18
01/19
16:09
01/19/18
16:09
Earnings
Sanmina reports Q1 preliminary adjusted EPS 48c, consensus 71c »

Reports Q1 preliminary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$332.26

-0.74 (-0.22%)

16:07
01/19/18
01/19
16:07
01/19/18
16:07
Periodicals
Breaking Periodicals news story on Lockheed Martin »

U.S. approves sale of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

CPLA

Capella Education

$80.50

0.7 (0.88%)

, STRA

Strayer

$93.08

0.9 (0.98%)

16:06
01/19/18
01/19
16:06
01/19/18
16:06
Hot Stocks
Capella Education shareholders approve proposed merger with Strayer »

Capella Education (CPLA)…

CPLA

Capella Education

$80.50

0.7 (0.88%)

STRA

Strayer

$93.08

0.9 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 19

    Jan

ADM

Archer Daniels

$40.61

0.13 (0.32%)

, BG

Bunge

$69.78

0.14 (0.20%)

16:03
01/19/18
01/19
16:03
01/19/18
16:03
Periodicals
Archer Daniels made takeover approach to Bunge, WSJ says »

Archer Daniels Midland…

ADM

Archer Daniels

$40.61

0.13 (0.32%)

BG

Bunge

$69.78

0.14 (0.20%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

C

Citi

$78.16

0.77 (0.99%)

16:01
01/19/18
01/19
16:01
01/19/18
16:01
Conference/Events
Citigroup to hold a conference call »

CFO Gerspach and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

GOLF

Acushnet Holdings

$21.50

0.65 (3.12%)

16:01
01/19/18
01/19
16:01
01/19/18
16:01
Hot Stocks
Acushnet Holdings acquires Linkgs & Kings, terms not disclosed »

Acushnet Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$69.79

0.145 (0.21%)

, ADM

Archer Daniels

$40.66

0.18 (0.44%)

15:58
01/19/18
01/19
15:58
01/19/18
15:58
Hot Stocks
Breaking Hot Stocks news story on Bunge, Archer Daniels »

Bunge jumps 10% after…

BG

Bunge

$69.79

0.145 (0.21%)

ADM

Archer Daniels

$40.66

0.18 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

BG

Bunge

$69.76

0.12 (0.17%)

, ADM

Archer Daniels

$40.66

0.18 (0.44%)

15:57
01/19/18
01/19
15:57
01/19/18
15:57
Periodicals
Breaking Periodicals news story on Bunge, Archer Daniels »

Archer Daniels made…

BG

Bunge

$69.76

0.12 (0.17%)

ADM

Archer Daniels

$40.66

0.18 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

HGT

Hugoton Royalty Trust

15:57
01/19/18
01/19
15:57
01/19/18
15:57
Hot Stocks
Breaking Hot Stocks news story on Hugoton Royalty Trust »

Hugoton Royalty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$41.85

0.17 (0.41%)

15:50
01/19/18
01/19
15:50
01/19/18
15:50
Options
Bullish option play in Comcast ahead of earnings next week »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.